Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Cos Eye US' Par Pharma (India)

This article was originally published in PharmAsia News

Executive Summary

Several major Indian pharmaceutical companies are considered possibilities to pursue a takeover of American drug manufacturer Par Pharmaceuticals. Ranbaxy is considered the most-likely choice by market insiders. The company has been looking for promising, U.S. acquisition prospects for some time and Par may represent an opportunity. Wockhardt, Sun Pharma, and Dr. Reddy's are also having their names tossed around. But all of the companies have declined to comment. In fact, Dr. Reddy's denied having any interest in acquiring a U.S.-based company. For its part, Par has several patented drugs in its pipeline; however, most of its interest is in generics. There has been some speculation that the company will sell off its off-patent and patented segments separately, in which case the Indian companies are expected to be interested solely in the generics. Par currently has 100 drugs approved by the U.S. Food and Drug Administration with another 49 applications in the works. (Click here for more

You may also be interested in...



‘Ready For Day 1’ – UK MHRA’s Statement Of Intent For Post-Brexit Medtech Regulatory System

The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.

African Platform Eyes $750m Investment

Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.

Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease

The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel